KR102271498B1 - 종양 치료를 위한 키누레닌 고갈 효소의 투여 - Google Patents

종양 치료를 위한 키누레닌 고갈 효소의 투여 Download PDF

Info

Publication number
KR102271498B1
KR102271498B1 KR1020167008486A KR20167008486A KR102271498B1 KR 102271498 B1 KR102271498 B1 KR 102271498B1 KR 1020167008486 A KR1020167008486 A KR 1020167008486A KR 20167008486 A KR20167008486 A KR 20167008486A KR 102271498 B1 KR102271498 B1 KR 102271498B1
Authority
KR
South Korea
Prior art keywords
leu
ala
gly
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167008486A
Other languages
English (en)
Korean (ko)
Other versions
KR20160048971A (ko
Inventor
조지 조지우
에버렛 스톤
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority to KR1020217019661A priority Critical patent/KR102442231B1/ko
Publication of KR20160048971A publication Critical patent/KR20160048971A/ko
Application granted granted Critical
Publication of KR102271498B1 publication Critical patent/KR102271498B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4244Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y307/00Hydrolases acting on carbon-carbon bonds (3.7)
    • C12Y307/01Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
    • C12Y307/01003Kynureninase (3.7.1.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167008486A 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여 Active KR102271498B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217019661A KR102442231B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361872132P 2013-08-30 2013-08-30
US61/872,132 2013-08-30
US201461986366P 2014-04-30 2014-04-30
US61/986,366 2014-04-30
PCT/US2014/053437 WO2015031771A2 (en) 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019661A Division KR102442231B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Publications (2)

Publication Number Publication Date
KR20160048971A KR20160048971A (ko) 2016-05-04
KR102271498B1 true KR102271498B1 (ko) 2021-07-05

Family

ID=52583559

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217019661A Active KR102442231B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여
KR1020167008486A Active KR102271498B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020217019661A Active KR102442231B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Country Status (12)

Country Link
US (5) US9808486B2 (enExample)
EP (2) EP3492094A1 (enExample)
JP (4) JP6307163B2 (enExample)
KR (2) KR102442231B1 (enExample)
CN (2) CN113957061A (enExample)
AU (1) AU2014312119B2 (enExample)
BR (1) BR112016004095A2 (enExample)
CA (2) CA2922670C (enExample)
ES (1) ES2707711T3 (enExample)
IL (2) IL244312B (enExample)
WO (1) WO2015031771A2 (enExample)
ZA (1) ZA201601443B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9808486B2 (en) * 2013-08-30 2017-11-07 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
IL250833B (en) * 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
JP2020527025A (ja) * 2017-07-12 2020-09-03 シンロジック オペレーティング カンパニー インコーポレイテッド 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
WO2019089740A1 (en) * 2017-11-03 2019-05-09 Dana-Farber Cancer Institute, Inc. Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Car t細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院(Dba西雅图儿童研究所) 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
WO2019204269A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
CN110412179A (zh) * 2018-04-26 2019-11-05 缪荣明 一种液相色谱检测颗粒酶a的方法
WO2020120982A2 (en) * 2018-12-14 2020-06-18 Autolus Limited Cell
BR112022007349A2 (pt) * 2019-10-17 2022-08-23 Ikena Oncology Inc Homodímero de quinureninase, método para produzir um homodímero de quinureninase peguilado, formulação farmacêutica e método para tratar um sujeito tendo um tumor
JPWO2023229024A1 (enExample) * 2022-05-27 2023-11-30
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
WO2003065984A2 (en) 2002-02-01 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease
CN1330774C (zh) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
EP2260846B1 (en) * 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
JP2008237022A (ja) * 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0625310D0 (en) * 2006-12-19 2007-01-24 Bioalvo Yeast platform construction and screening methods
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2656414T3 (es) 2010-09-08 2018-02-27 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20120085209A (ko) * 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
EP2753315B1 (en) * 2011-09-07 2017-03-01 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
US9868774B2 (en) 2011-10-20 2018-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
US9808486B2 (en) 2013-08-30 2017-11-07 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
JP6912171B2 (ja) * 2016-09-15 2021-07-28 株式会社トプコン 眼科検査装置
WO2019204269A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Med Chem. 2009, Vol.52, No.2, pp.389-396

Also Published As

Publication number Publication date
CA3173052A1 (en) 2015-03-05
BR112016004095A2 (pt) 2017-10-17
CN105722522A (zh) 2016-06-29
EP3038636B1 (en) 2018-11-07
EP3492094A1 (en) 2019-06-05
US9808486B2 (en) 2017-11-07
EP3038636A2 (en) 2016-07-06
KR20210082264A (ko) 2021-07-02
AU2014312119B2 (en) 2019-09-19
NZ717492A (en) 2021-10-29
US10772913B2 (en) 2020-09-15
JP6307163B2 (ja) 2018-04-04
JP2018127463A (ja) 2018-08-16
WO2015031771A3 (en) 2015-05-14
US20200054674A1 (en) 2020-02-20
KR20160048971A (ko) 2016-05-04
ES2707711T3 (es) 2019-04-04
IL244312B (en) 2019-03-31
AU2014312119A1 (en) 2016-03-17
KR102442231B1 (ko) 2022-09-13
WO2015031771A2 (en) 2015-03-05
CN105722522B (zh) 2021-10-19
US20170056449A1 (en) 2017-03-02
CN113957061A (zh) 2022-01-21
US20210213059A1 (en) 2021-07-15
CA2922670A1 (en) 2015-03-05
EP3038636A4 (en) 2017-04-26
US20150064154A1 (en) 2015-03-05
JP2016533753A (ja) 2016-11-04
JP7029316B2 (ja) 2022-03-03
JP2022159570A (ja) 2022-10-17
ZA201601443B (en) 2019-08-28
IL264901B (en) 2019-08-29
US20240091258A1 (en) 2024-03-21
JP2020111611A (ja) 2020-07-27
IL244312A0 (en) 2016-04-21
US11534463B2 (en) 2022-12-27
CA2922670C (en) 2022-11-29

Similar Documents

Publication Publication Date Title
KR102271498B1 (ko) 종양 치료를 위한 키누레닌 고갈 효소의 투여
US11168142B2 (en) Administration of kynurenine depleting enzymes for tumor therapy
KR102269209B1 (ko) 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소
KR20160045096A (ko) 치료적 목적을 위한 조작된 영장류 l-메티오니나제
KR102862473B1 (ko) 인간 키누레니나제 효소 및 이의 사용법
HK1226335A1 (en) Administration of kynurenine depleting enzymes for tumor therapy
HK1226335B (en) Administration of kynurenine depleting enzymes for tumor therapy
NZ717492B2 (en) Administration of kynurenine depleting enzymes for tumor therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160330

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190828

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200520

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210325

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210624

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210625

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210628

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 4

End annual number: 4